Developer docs
API playgroundTry for free, no card

Search company profiles

ScreenPoint Medical

Full company profile

uuid0000bm7

Namestring
ScreenPoint Medical
Legal namestring
ScreenPoint Medical B.V.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ScreenPoint Medical B.V. is a privately held Dutch AI healthcare company founded in 2014 as a spin-off of Radboud University Medical Center, headquartered in Nijmegen, the Netherlands, with US regional headquarters in New York and an engineering/research footprint in Copenhagen, Denmark. The company develops the Transpara Breast AI Suite, a deep-learning-based clinical decision support platform that analyzes both 2D (FFDM) and 3D (DBT) mammograms. The suite comprises three modules: Transpara Detection (which assigns per-region cancer risk on a 98-point scale and classifies exams as Elevated, Intermediate, or Low Risk, with a 99.97% negative predictive value on Low Risk exams), Transpara Density (combining BI-RADS-like composition with volumetric breast density trained on MRI ground truth), and Transpara Temporal Comparison (which analyzes findings across up to three prior mammograms, increasing Elevated/Intermediate sensitivity by up to 8% and reducing false positives by 37%).

The platform is vendor-agnostic, integrating across PACS systems (Sectra, GE), imaging OEMs (Fujifilm, Siemens Healthineers, Canon/Fomei), and AI orchestration platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Health Model Hub, Incepto, Synthesis Health, Ikonopedia, NTT Data). Transpara is FDA-cleared (K241831, K232096) and CE-marked under EU MDR (Notified Body 0344) for both 2D and 3D mammography, cleared for sale in 40 countries, and has processed more than 12 million mammograms across 30+ countries. It is the only breast AI solution included in randomized controlled trials — MASAI in Sweden (105,000+ women, results published in The Lancet showing 29% increase in cancer detection, 44% reduction in radiologist workload, and a 12% reduction in interval cancers), PRISM in the US (400,000 exams, $16M PCORI-funded), and AIMS in Norway (140,000+ women) — and is backed by 55+ peer-reviewed publications.

ScreenPoint generates revenue primarily through enterprise SaaS / multi-year subscription licenses to hospitals, academic medical centers, radiology practices, and national or regional screening programs, with pricing conducted on a quote-based, undisclosed basis. A complementary usage-based revenue stream exists where imaging-center chains resell Transpara as a paid per-study add-on (e.g., the $40 mammography AI add-on launched by Rayus Radiology at its ~150 outpatient imaging centers). Non-dilutive research grants (EFRO, Health~Holland, PCORI) supplement R&D funding. The company has raised $49M in total capital from Insight Partners and Siemens Healthineers, employs 51–100 people, and operates in customer segments including direct enterprise sales to hospital systems, channel and OEM partnerships, and public-health-system procurement. In January 2025, ScreenPoint acquired Biomediq A/S (Denmark) to expand into breast cancer risk assessment, and the company continues to publish consecutive algorithm updates (Transpara 2.1) and secure flagship integrations (Microsoft Precision Imaging Network, December 2025).

Short descriptiontext

ScreenPoint Medical develops the Transpara Breast AI Suite, a deep-learning platform for detecting breast cancer in 2D and 3D mammograms, serving hospitals, academic medical centers, radiology practices, and national screening programs across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast cancer screening AI, mammography image analysis, deep learning radiology, clinical decision support, medical imaging software
Industry3 codes
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code3 codes
  • Diagnostic Imaging Centers621512
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Medical Imaging AI / Breast Cancer Screening Software
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise SaaS / software subscription for Transpara Breast AI
TypeSubscription Recurring
Description

Primary revenue stream based on licensing the Transpara Detection, Density, and Temporal Comparison modules to hospitals, academic medical centers, radiology practices, and national/regional screening programs. Quote-based pricing (not publicly disclosed) and multi-year contracts inferred from enterprise sales motion and Schedule Demo lead capture.

screenpoint-medical.com
2Per-study AI add-on services (e.g., $40 mammography AI add-on at Rayus Radiology)
TypeUsage Based
Description

Pricing in some partner-distributed deployments is on a per-study/per-exam basis; for example, Rayus Radiology launched a $40 mammography AI add-on service using Transpara at its outpatient imaging centers.

radiologybusiness.com
3Research grant and non-dilutive funding (e.g., EFRO, Health~Holland)
TypeManaged Services
Description

Non-dilutive research grants from bodies such as the European Fund for Regional Development (EFRO Oost) and Health~Holland fund specific research initiatives (Autonomous AI for Cancer Detection, aiEMBRACE). These grants supplement R&D but are not core commercial revenue.

screenpoint-medical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Quote-based enterprise subscription; pricing not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed; customers engage via 'Schedule Demo' to receive a tailored quote. Typical of enterprise medical imaging AI deployments with multi-year contracts.

screenpoint-medical.com
2$40 per-study mammography AI add-on (as offered by Rayus Radiology using Transpara)
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Rayus Radiology launched a $40 mammography AI add-on service using Transpara Breast AI at 14 outpatient imaging centers in Washington state, with plans to expand across ~150 centers nationally.

radiologybusiness.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Transpara
Description

Flagship Breast AI product suite from ScreenPoint Medical, including detection, density assessment, and temporal comparison capabilities for 2D and 3D mammography.

screenpoint-medical.com
+3 more records
Core offering1 text field

ScreenPoint Medical develops and licenses the Transpara Breast AI Suite — deep-learning based clinical decision-support software that analyzes 2D (FFDM) and 3D (DBT) mammograms to detect breast cancer, assess breast density, and compare findings against prior exams. The platform integrates within existing PACS and AI platforms and is sold via enterprise subscriptions and per-study licensing to hospitals, radiology practices, and national screening programs in 30+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • 29% increase in cancer detection rate (MASAI RCT, 105,000+ women)
+11 more records
Product overview1 text field

ScreenPoint Medical offers a single platform-plus-modules architecture built around the Transpara Breast AI Suite. The suite consists of a core module, Transpara Detection (AI breast cancer detection for 2D/3D mammography), and complementary add-on modules: Transpara Density (automated BI-RADS-like and volumetric breast density reporting) and Transpara Temporal Comparison (AI comparison against up to three prior mammograms). These modules work together to provide a 'second pair of eyes' for radiologists, delivering cancer detection, density assessment, and change-over-time analysis within existing PACS and AI platforms (e.g., Aidoc aiOS, Microsoft for Healthcare Precision Imaging Network, Ferrum Health Model Hub, and Ikonopedia). The suite is FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Product and service4 records
1Transpara Detection
CategoryAI breast cancer detection (core product)
Description

AI-driven breast cancer detection tool for 2D mammography (FFDM) and 3D mammography (DBT) that categorizes exams into Elevated, Intermediate, or Low Risk using a 98-point region risk scale; Low Risk exams have a 99.97% negative predictive value. FDA-cleared (K241831, K232096) and CE-marked under MDR; deployed in 30+ countries with 12M+ mammograms processed.

2Transpara Density
CategoryBreast density assessment (add-on module)
Description

Automated breast density assessment combining a BI-RADS-like composition assessment (5th Ed.) with a volumetric breast density (VBD) measurement trained against MRI ground truth. Supports MQSA Final Rule compliance in the USA and integration with the IBIS / Tyrer-Cuzick V8 risk model. Available for both FFDM and DBT.

3Transpara Temporal Comparison
CategoryPrior mammogram comparison (add-on module)
Description

AI feature that tracks findings across up to three prior mammograms (9 months to 6.5 years prior), increasing the sensitivity of Elevated and Intermediate Risk Scores by up to 8% and reducing false positives by 37% at 71% sensitivity based on internal analysis and ECR 2025 research.

4Transpara Breast AI Suite
CategoryAI platform / breast imaging decision-support suite
Description

Integrated suite of AI applications for the breast imaging continuum combining Transpara Detection (cancer detection), Transpara Density (breast density reporting), and Transpara Temporal Comparison (prior comparison). Designed as a vendor-agnostic decision-support layer that works within existing PACS, AI platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Model Hub), and mammography acquisition environments. FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-24
Description

Partnership announced September 24, 2025 at EUSOBI 2025 to deploy Transpara Detection, Density, and Temporal Comparison across approximately 15-17 breast cancer screening centers in the Castilla y León region of Spain; serves women aged 45-74 in a Ministry of Health-run program. Sacyl selected ScreenPoint after extensive vendor comparison.

2Biomediq A/S
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-08
Description

Acquired by ScreenPoint Medical on January 8, 2025 to expand breast cancer risk assessment capabilities. Biomediq A/S specializes in quantitative imaging biomarkers for breast cancer risk assessment; the acquisition enhances Transpara's risk prediction capabilities based on prior collaborative research.

prnewswire.co.uk
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Strategic partnership offering Fujifilm customers Transpara as integrated clinical decision-support for women's health imaging. Fujifilm quote: 'Fujifilm is thrilled to form and expand partnerships with leading companies that share the same commitment to improve patient lives through advances in breast imaging technology.' Christine Murray is Women's Health Marketing Director at Fujifilm Healthcare Americas.

Strategic tierFlagshipTypeTechnology or Integration
Description

Strategic technology integration partner. Aidoc's aiOS platform will host Transpara as part of the PRISM RCT clinical workflow integration. Tom Valent, VP of Business Development at Aidoc, cited ScreenPoint as 'the ideal partner for Aidoc in the women's health space.'

Strategic tierFlagshipTypeTechnology or Integration
Description

Commercial agreement announced December 1, 2025 making the Transpara breast-imaging AI portfolio available through Precision Imaging Network, part of Microsoft for Healthcare. Simplifies cloud-enabled access to Breast AI tools within existing clinical ecosystems. Quote from Vikram Chhabra, General Manager, Diagnostic Solutions at Microsoft.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership announced January 2026 to offer Transpara Breast AI through Ferrum's AI Governance Suite / Model Hub. Peter Eason, COO of Ferrum Health, stated the availability on Ferrum's Model Hub reflects health systems' demand for 'proven performance, real-world scale, and trust.'

Strategic tierCoreTypeTechnology or Integration
Description

Imaging technology and PACS integration partner. Transpara integrates with GE Healthcare software offerings to deliver breast AI insights within clinical workflows.

Strategic tierCoreTypeTechnology or Integration
Description

PACS integration partner; Transpara integrates into Sectra's reading environment to deliver breast AI insights without disrupting radiologist workflow.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership announced June 14, 2025 providing radiologists with automated AI insights for more accurate and productive patient diagnoses and care. Emily Crane is CEO & President of Ikonopedia.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor providing AI for breast cancer detection in the United Arab Emirates market.

11EGT (Middle East & Africa)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor covering the Middle East and Africa region.

screenpoint-medical.com
12Answer Medical Solutions
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Channel partner for distribution and deployment in regional markets.

screenpoint-medical.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional partner covering Czech Republic and adjacent markets for breast imaging distribution.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional consulting and distribution partner for Transpara deployment.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

ScreenPoint Medical was founded as a spin-off of Radboud University Medical Center (home of co-founder Professor Nico Karssemeijer). Active research collaborator on the EFRO 'Autonomous AI for Cancer Detection' project (with Thirona) and aiEMBRACE (with NKI, Memorial Sloan Kettering, Radboudumc). Project runtime Nov 2023 – Nov 2026.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner in the aiEMBRACE project (Nov 2023 – Nov 2026) advancing AI-based technology to support women at elevated risk through the breast cancer patient journey. Other aiEMBRACE partners include Memorial Sloan Kettering and Radboudumc.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner in the aiEMBRACE project developing MRI breast cancer detection algorithms, risk algorithms for future breast cancer development, cancer recurrence prediction, and treatment response monitoring.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner on the EFRO-funded 'Autonomous AI for Cancer Detection' project (Jan 2025 – End of 2027) developing AI tools for early detection of breast and lung cancer, alongside Radboud UMC and ScreenPoint Medical.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

France-based AI mammography vendor with MammoScreen 2.0 FDA-cleared for breast cancer detection on 2D mammograms. Direct competitor to Transpara Detection in radiology practice and screening program RFPs, particularly in Europe and the US.

TypeDirect peer
Description

South Korean AI medical imaging company with Lunit INSIGHT MMG for mammography, FDA-cleared and CE-marked. Direct competitor to Transpara in breast cancer detection, with strong publication record and global screening program ambitions.

TypeDirect peer
Description

Legacy breast AI vendor offering ProFound AI for DBT and breast density assessment, now part of Bracco's imaging business. Direct competitor across Transpara's Detection and Density modules, especially in US radiology practices.

TypeDirect peer
Description

New Zealand/US company specializing in AI-driven breast density, risk assessment, and quality assurance. Directly comparable on the Density and risk-modeling side of Transpara, with strong US mammography practice footprint.

TypeEmerging player
Description

RadNet subsidiary (incorporating iCAD's breast AI assets) commercializing breast cancer detection and density AI across RadNet's ~370 imaging centers. Emerging player pursuing integrated screening program deployments comparable to Transpara.

TypeBroad incumbent
Description

Major mammography OEM (3Dimensions, Genius AI) with embedded AI capabilities and a global installed base. Broad incumbent that competes via bundled hardware-AI offerings rather than standalone vendor-neutral software.

TypeBroad incumbent
Description

Major imaging OEM with mammography, PACS, and AI capabilities (Edison platform). Broad incumbent and existing integration partner; could substitute Transpara with native AI in customer negotiations.

TypeBroad incumbent
Description

Imaging OEM and existing Transpara partner; competes via women's health portfolio that may include bundled breast AI capabilities. Broad incumbent in DBT mammography.

TypeEmerging player
Description

Canadian AI vendor specializing in breast density, image quality, and mammography reporting analytics. Emerging player focused on a subset of Transpara's Density and quality assurance modules.

TypeOthers
Description

Clinical AI platform with aiOS that hosts multi-specialty AI including Transpara for the PRISM RCT. Adjacent infrastructure partner that could either remain a partner or vertically integrate breast AI capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers21 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration17 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ScreenPoint Medical

Medical Imaging AI / Breast Cancer Screening Softwarescreenpoint-medical.com

ScreenPoint Medical develops the Transpara Breast AI Suite, a deep-learning platform for detecting breast cancer in 2D and 3D mammograms, serving hospitals, academic medical centers, radiology practices, and national screening programs across 30+ countries.

What ScreenPoint Medical does

ScreenPoint Medical B.V. is a privately held Dutch AI healthcare company founded in 2014 as a spin-off of Radboud University Medical Center, headquartered in Nijmegen, the Netherlands, with US regional headquarters in New York and an engineering/research footprint in Copenhagen, Denmark. The company develops the Transpara Breast AI Suite, a deep-learning-based clinical decision support platform that analyzes both 2D (FFDM) and 3D (DBT) mammograms. The suite comprises three modules: Transpara Detection (which assigns per-region cancer risk on a 98-point scale and classifies exams as Elevated, Intermediate, or Low Risk, with a 99.97% negative predictive value on Low Risk exams), Transpara Density (combining BI-RADS-like composition with volumetric breast density trained on MRI ground truth), and Transpara Temporal Comparison (which analyzes findings across up to three prior mammograms, increasing Elevated/Intermediate sensitivity by up to 8% and reducing false positives by 37%).

The platform is vendor-agnostic, integrating across PACS systems (Sectra, GE), imaging OEMs (Fujifilm, Siemens Healthineers, Canon/Fomei), and AI orchestration platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Health Model Hub, Incepto, Synthesis Health, Ikonopedia, NTT Data). Transpara is FDA-cleared (K241831, K232096) and CE-marked under EU MDR (Notified Body 0344) for both 2D and 3D mammography, cleared for sale in 40 countries, and has processed more than 12 million mammograms across 30+ countries. It is the only breast AI solution included in randomized controlled trials — MASAI in Sweden (105,000+ women, results published in The Lancet showing 29% increase in cancer detection, 44% reduction in radiologist workload, and a 12% reduction in interval cancers), PRISM in the US (400,000 exams, $16M PCORI-funded), and AIMS in Norway (140,000+ women) — and is backed by 55+ peer-reviewed publications.

ScreenPoint generates revenue primarily through enterprise SaaS / multi-year subscription licenses to hospitals, academic medical centers, radiology practices, and national or regional screening programs, with pricing conducted on a quote-based, undisclosed basis. A complementary usage-based revenue stream exists where imaging-center chains resell Transpara as a paid per-study add-on (e.g., the $40 mammography AI add-on launched by Rayus Radiology at its ~150 outpatient imaging centers). Non-dilutive research grants (EFRO, Health~Holland, PCORI) supplement R&D funding. The company has raised $49M in total capital from Insight Partners and Siemens Healthineers, employs 51–100 people, and operates in customer segments including direct enterprise sales to hospital systems, channel and OEM partnerships, and public-health-system procurement. In January 2025, ScreenPoint acquired Biomediq A/S (Denmark) to expand into breast cancer risk assessment, and the company continues to publish consecutive algorithm updates (Transpara 2.1) and secure flagship integrations (Microsoft Precision Imaging Network, December 2025).

ScreenPoint Medical firmographics

Firmographics
Name
ScreenPoint Medical
Legal name
ScreenPoint Medical B.V.
Website
https://screenpoint-medical.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
ScreenPoint Medical develops the Transpara Breast AI Suite, a deep-learning platform for detecting breast cancer in 2D and 3D mammograms, serving hospitals, academic medical centers, radiology practices, and national screening programs across 30+ countries.
Ownership category
akta.pro rank

ScreenPoint Medical industry classification

Industry
Product category
Medical Imaging AI / Breast Cancer Screening Software
NAICS
Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLALAFAD
Oncology Remote Symptom Monitoring & Care Navigation
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Breast cancer screening AI
  • Mammography image analysis
  • Deep learning radiology
  • Clinical decision support
  • Medical imaging software

Where ScreenPoint Medical is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices3 records

Markets served

ScreenPoint Medical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise SaaS / software subscription for Transpara Breast AI: Primary revenue stream based on licensing the Transpara Detection, Density, and Temporal Comparison modules to hospitals, academic medical centers, radiology practices, and national/regional screening programs. Quote-based pricing (not publicly disclosed) and multi-year contracts inferred from enterprise sales motion and Schedule Demo lead capture.
  2. Per-study AI add-on services (e.g., $40 mammography AI add-on at Rayus Radiology): Pricing in some partner-distributed deployments is on a per-study/per-exam basis; for example, Rayus Radiology launched a $40 mammography AI add-on service using Transpara at its outpatient imaging centers.
  3. Research grant and non-dilutive funding (e.g., EFRO, Health~Holland): Non-dilutive research grants from bodies such as the European Fund for Regional Development (EFRO Oost) and Health~Holland fund specific research initiatives (Autonomous AI for Cancer Detection, aiEMBRACE). These grants supplement R&D but are not core commercial revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise subscription; pricing not publicly disclosed
Usage-basedPay-as-you-go$40 per-study mammography AI add-on (as offered by Rayus Radiology using Transpara)

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

ScreenPoint Medical product offering

Product offering

Core offering

ScreenPoint Medical develops and licenses the Transpara Breast AI Suite — deep-learning based clinical decision-support software that analyzes 2D (FFDM) and 3D (DBT) mammograms to detect breast cancer, assess breast density, and compare findings against prior exams. The platform integrates within existing PACS and AI platforms and is sold via enterprise subscriptions and per-study licensing to hospitals, radiology practices, and national screening programs in 30+ countries.

Product overview

ScreenPoint Medical offers a single platform-plus-modules architecture built around the Transpara Breast AI Suite. The suite consists of a core module, Transpara Detection (AI breast cancer detection for 2D/3D mammography), and complementary add-on modules: Transpara Density (automated BI-RADS-like and volumetric breast density reporting) and Transpara Temporal Comparison (AI comparison against up to three prior mammograms). These modules work together to provide a 'second pair of eyes' for radiologists, delivering cancer detection, density assessment, and change-over-time analysis within existing PACS and AI platforms (e.g., Aidoc aiOS, Microsoft for Healthcare Precision Imaging Network, Ferrum Health Model Hub, and Ikonopedia). The suite is FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Transpara: Flagship Breast AI product suite from ScreenPoint Medical, including detection, density assessment, and temporal comparison capabilities for 2D and 3D mammography.
  • Transpara Detection
  • Transpara Density
  • Transpara Temporal Comparison

Products and services

  • Transpara Detection AI-driven breast cancer detection tool for 2D mammography (FFDM) and 3D mammography (DBT) that categorizes exams into Elevated, Intermediate, or Low Risk using a 98-point region risk scale; Low Risk exams have a 99.97% negative predictive value. FDA-cleared (K241831, K232096) and CE-marked under MDR; deployed in 30+ countries with 12M+ mammograms processed.
  • Transpara Density Automated breast density assessment combining a BI-RADS-like composition assessment (5th Ed.) with a volumetric breast density (VBD) measurement trained against MRI ground truth. Supports MQSA Final Rule compliance in the USA and integration with the IBIS / Tyrer-Cuzick V8 risk model. Available for both FFDM and DBT.
  • Transpara Temporal Comparison AI feature that tracks findings across up to three prior mammograms (9 months to 6.5 years prior), increasing the sensitivity of Elevated and Intermediate Risk Scores by up to 8% and reducing false positives by 37% at 71% sensitivity based on internal analysis and ECR 2025 research.
  • Transpara Breast AI Suite Integrated suite of AI applications for the breast imaging continuum combining Transpara Detection (cancer detection), Transpara Density (breast density reporting), and Transpara Temporal Comparison (prior comparison). Designed as a vendor-agnostic decision-support layer that works within existing PACS, AI platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Model Hub), and mammography acquisition environments. FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Quantifiable outcome

  • 29% increase in cancer detection rate (MASAI RCT, 105,000+ women)
  • +11 more outcomes

Companies that use ScreenPoint Medical

Customer profile

Named customers21 records

Segments6 records

Ideal customer profiles4 records

ScreenPoint Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration17 records

AI capability7 records

Feature6 records

ScreenPoint Medical partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered flagship, core and minor.

  • Sacyl (Castilla y León regional health system, Spain)flagshipChannel Partner/ Reseller/ Distributor · 24 September 2025Partnership announced September 24, 2025 at EUSOBI 2025 to deploy Transpara Detection, Density, and Temporal Comparison across approximately 15-17 breast cancer screening centers in the Castilla y León region of Spain; serves women aged 45-74 in a Ministry of Health-run program. Sacyl selected ScreenPoint after extensive vendor comparison.
  • Biomediq A/ScoreStrategic or Co-development Partner · 8 January 2025Acquired by ScreenPoint Medical on January 8, 2025 to expand breast cancer risk assessment capabilities. Biomediq A/S specializes in quantitative imaging biomarkers for breast cancer risk assessment; the acquisition enhances Transpara's risk prediction capabilities based on prior collaborative research.
  • Fujifilm Healthcare AmericascoreOEM/ Whitelabel/ Licensing PartnerStrategic partnership offering Fujifilm customers Transpara as integrated clinical decision-support for women's health imaging. Fujifilm quote: 'Fujifilm is thrilled to form and expand partnerships with leading companies that share the same commitment to improve patient lives through advances in breast imaging technology.' Christine Murray is Women's Health Marketing Director at Fujifilm Healthcare Americas.
  • AidocflagshipTechnology or IntegrationStrategic technology integration partner. Aidoc's aiOS platform will host Transpara as part of the PRISM RCT clinical workflow integration. Tom Valent, VP of Business Development at Aidoc, cited ScreenPoint as 'the ideal partner for Aidoc in the women's health space.'
  • Microsoft (Precision Imaging Network, part of Microsoft for Healthcare)flagshipTechnology or IntegrationCommercial agreement announced December 1, 2025 making the Transpara breast-imaging AI portfolio available through Precision Imaging Network, part of Microsoft for Healthcare. Simplifies cloud-enabled access to Breast AI tools within existing clinical ecosystems. Quote from Vikram Chhabra, General Manager, Diagnostic Solutions at Microsoft.
  • Ferrum HealthcoreTechnology or IntegrationPartnership announced January 2026 to offer Transpara Breast AI through Ferrum's AI Governance Suite / Model Hub. Peter Eason, COO of Ferrum Health, stated the availability on Ferrum's Model Hub reflects health systems' demand for 'proven performance, real-world scale, and trust.'
  • GE HealthcarecoreTechnology or IntegrationImaging technology and PACS integration partner. Transpara integrates with GE Healthcare software offerings to deliver breast AI insights within clinical workflows.
  • SectracoreTechnology or IntegrationPACS integration partner; Transpara integrates into Sectra's reading environment to deliver breast AI insights without disrupting radiologist workflow.
  • IkonopediacoreTechnology or IntegrationIntegration partnership announced June 14, 2025 providing radiologists with automated AI insights for more accurate and productive patient diagnoses and care. Emily Crane is CEO & President of Ikonopedia.
  • ARJ (Medical UAE)minorChannel Partner/ Reseller/ DistributorRegional distributor providing AI for breast cancer detection in the United Arab Emirates market.
  • EGT (Middle East & Africa)minorChannel Partner/ Reseller/ DistributorRegional distributor covering the Middle East and Africa region.
  • Answer Medical SolutionsminorChannel Partner/ Reseller/ DistributorChannel partner for distribution and deployment in regional markets.
  • Fomei (Czech Republic / Canon)minorChannel Partner/ Reseller/ DistributorRegional partner covering Czech Republic and adjacent markets for breast imaging distribution.
  • Medicore ConsultminorChannel Partner/ Reseller/ DistributorRegional consulting and distribution partner for Transpara deployment.
  • Radboud University Medical Center (Radboudumc)flagshipStrategic or Co-development PartnerScreenPoint Medical was founded as a spin-off of Radboud University Medical Center (home of co-founder Professor Nico Karssemeijer). Active research collaborator on the EFRO 'Autonomous AI for Cancer Detection' project (with Thirona) and aiEMBRACE (with NKI, Memorial Sloan Kettering, Radboudumc). Project runtime Nov 2023 – Nov 2026.
  • Netherlands Cancer Institute (NKI-AVL)coreStrategic or Co-development PartnerResearch partner in the aiEMBRACE project (Nov 2023 – Nov 2026) advancing AI-based technology to support women at elevated risk through the breast cancer patient journey. Other aiEMBRACE partners include Memorial Sloan Kettering and Radboudumc.
  • Memorial Sloan Kettering Cancer Center (MSKCC)coreStrategic or Co-development PartnerResearch partner in the aiEMBRACE project developing MRI breast cancer detection algorithms, risk algorithms for future breast cancer development, cancer recurrence prediction, and treatment response monitoring.
  • ThironacoreStrategic or Co-development PartnerResearch partner on the EFRO-funded 'Autonomous AI for Cancer Detection' project (Jan 2025 – End of 2027) developing AI tools for early detection of breast and lung cancer, alongside Radboud UMC and ScreenPoint Medical.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

ScreenPoint Medical competitors and assessment

Company assessment

Direct peers

  • Therapixel: France-based AI mammography vendor with MammoScreen 2.0 FDA-cleared for breast cancer detection on 2D mammograms. Direct competitor to Transpara Detection in radiology practice and screening program RFPs, particularly in Europe and the US.
  • Lunit: South Korean AI medical imaging company with Lunit INSIGHT MMG for mammography, FDA-cleared and CE-marked. Direct competitor to Transpara in breast cancer detection, with strong publication record and global screening program ambitions.
  • iCAD (Bracco): Legacy breast AI vendor offering ProFound AI for DBT and breast density assessment, now part of Bracco's imaging business. Direct competitor across Transpara's Detection and Density modules, especially in US radiology practices.
  • Volpara Health: New Zealand/US company specializing in AI-driven breast density, risk assessment, and quality assurance. Directly comparable on the Density and risk-modeling side of Transpara, with strong US mammography practice footprint.

Emerging players

  • DeepHealth (RadNet): RadNet subsidiary (incorporating iCAD's breast AI assets) commercializing breast cancer detection and density AI across RadNet's ~370 imaging centers. Emerging player pursuing integrated screening program deployments comparable to Transpara.
  • Densitas: Canadian AI vendor specializing in breast density, image quality, and mammography reporting analytics. Emerging player focused on a subset of Transpara's Density and quality assurance modules.

Broad incumbents

  • Hologic: Major mammography OEM (3Dimensions, Genius AI) with embedded AI capabilities and a global installed base. Broad incumbent that competes via bundled hardware-AI offerings rather than standalone vendor-neutral software.
  • GE HealthCare: Major imaging OEM with mammography, PACS, and AI capabilities (Edison platform). Broad incumbent and existing integration partner; could substitute Transpara with native AI in customer negotiations.
  • Fujifilm Healthcare: Imaging OEM and existing Transpara partner; competes via women's health portfolio that may include bundled breast AI capabilities. Broad incumbent in DBT mammography.

Others

  • Aidoc: Clinical AI platform with aiOS that hosts multi-specialty AI including Transpara for the PRISM RCT. Adjacent infrastructure partner that could either remain a partner or vertically integrate breast AI capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ScreenPoint Medical social profiles

Digital presence

ScreenPoint Medical compliance and trust

Trust signal

Compliance5 records

ScreenPoint Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ScreenPoint Medical leadership team

Management profile

Number of profiles

Profiles10 records

ScreenPoint Medical subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

ScreenPoint Medical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ScreenPoint Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScreenPoint Medical

What does ScreenPoint Medical do?

ScreenPoint Medical develops and licenses the Transpara Breast AI Suite — deep-learning based clinical decision-support software that analyzes 2D (FFDM) and 3D (DBT) mammograms to detect breast cancer, assess breast density, and compare findings against prior exams. The platform integrates within existing PACS and AI platforms and is sold via enterprise subscriptions and per-study licensing to hospitals, radiology practices, and national screening programs in 30+ countries.

Is ScreenPoint Medical a public or private company?

ScreenPoint Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was ScreenPoint Medical founded?

ScreenPoint Medical was founded in 2014. It employs 51 to 100 people.

Where is ScreenPoint Medical based?

ScreenPoint Medical is headquartered in Nijmegen, Netherlands, in the Europe region.

How does ScreenPoint Medical make money?

Three revenue lines are on record. Enterprise SaaS / software subscription for Transpara Breast AI is the primary driver. The others are per-study AI add-on services (e.g., $40 mammography AI add-on at Rayus Radiology) and research grant and non-dilutive funding (e.g., EFRO, Health~Holland).

Who are ScreenPoint Medical's main competitors?

Direct peers on record are Therapixel, Lunit, iCAD (Bracco) and Volpara Health. Emerging players are DeepHealth (RadNet) and Densitas. Broad incumbents are Hologic, GE HealthCare and Fujifilm Healthcare. Aidoc is listed as an others.

Does ScreenPoint Medical have an API?

No public API is recorded for ScreenPoint Medical.

What industry is ScreenPoint Medical in?

ScreenPoint Medical's product category is Medical Imaging AI / Breast Cancer Screening Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621512 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireScreenPoint Medical Appoints Parul Sharma as Chief Commercial OfficerScreenPoint Medical appointed Parul Sharma as Chief Commercial Officer to lead global go-to-market strategy. She previously served as CCO at Viedoc and has held C-level roles since 2016. The company has processed over 15 million mammograms worldwide.StartupmafiaScreenPoint Medical Raises €13.6M to Advance AI-Powered Breast Cancer DetectionScreenPoint Medical raised €13.6M in funding, including €11.9M from existing investors and €1.7M in grants. Its AI platform Transpara has processed over 12 million mammograms and is deployed in 30+ countries. The company plans to expand globally and accelerate product innovation.VentureRadarNew Funding Rounds in workflow aiThe article reports on multiple funding rounds for various companies developing AI-enabled products and services, including Omni Analytics, BuildForever, Courier Health, NeoCognition, RIIG, ASMOne, Loop Payments, ScreenPoint Medical, Ultralight, and Zenskar.BioWorldFinancings for April 21, 2026On April 21, 2026, biopharma and med-tech companies including Alamar, Amanat, Marvel, Mobia, Modular, Odyssey, Prelude, Revolution, Screenpoint, and Sharp raised funds through public or private financings. The list covers both public and private financing activities for these firms.Medical Device NetworkScreenPoint Medical raises $16m with continued investment from Siemens HealthineersScreenPoint Medical, a Netherlands-based AI healthcare company, has raised $16 million in funding to advance global expansion of its Transpara AI breast cancer screening tool, with continued participation from Siemens Healthineers. The funding comprised $14 million from VC firm Insight Partners and existing investors, plus $2 million from non-dilutive research grants, bringing the company's total raised capital to $49 million. The Transpara tool, which gained FDA clearance in December 2024, has demonstrated clinical effectiveness including a 12% reduction in interval cancers and a 63.6% reduction in radiologist workload according to published research.EU-StartupsInsight Partners-backed ScreenPoint Medical secures €13.6 million to advance AI-powered breast cancer detectionScreenPoint Medical, a Nijmegen-based AI company focused on breast cancer detection, has raised €11.9 million in new funding from existing investors Insight Partners and Siemens Healthineers, plus an additional €1.7 million in non-dilutive research grants, totaling €13.6 million. The funding will support product innovation, international expansion, and strategic initiatives to reinforce the company's role in breast cancer care. The company's Transpara AI product is deployed in 30+ countries processing over 12 million mammograms and was validated in a randomized controlled trial published in The Lancet that showed a 29% boost in cancer detection.TechStartupsTop Startup and Tech Funding News – April 20 2025On April 20, 2026, multiple startups raised capital across AI, robotics, healthcare, and climate sectors. Recursive Superintelligence raised over $500M, X Square Robot raised $276M, and Pulnovo Medical raised $100M, with other rounds totaling over $400M. The funding reflects investor interest in AI systems operating in physical environments and applied AI in healthcare workflows.TechStartupsUber deepens bet on Delivery Hero in $318M deal amid EU merger pressure on ProsusUber agreed to buy an additional 4.5% stake in Delivery Hero from Prosus for about €270 million, paying €20 per share. The deal reduces Prosus's stake to roughly 21% and is tied to EU approval of its €4.1 billion Just Eat acquisition. Uber's growing stake signals confidence in Delivery Hero's scale model amid shifting European merger rules.FinSMEsScreenPoint Medical Raises $14M in FundingScreenPoint Medical, a Dutch AI breast cancer detection provider, raised $14M led by Insight Partners and Siemens Healthineers. The round follows $2M in non-dilutive grants, totaling $16M, to fund product innovation, international expansion, and strategic initiatives.YahooScreenPoint Medical raises $16m with continued investment from Siemens HealthineersScreenPoint Medical, a Netherlands-based medical technology company, has raised $16 million in funding to advance the global expansion of its Transpara Breast AI screening tool for breast cancer detection, with continued participation from Siemens Healthineers. Of the total, $14 million came from VC firm Insight Partners and other existing investors, while $2 million originated from non-dilutive research grants, bringing ScreenPoint's total funding to $49 million. The AI tool, which received FDA clearance in December 2024 and a European CE mark in 2018, has demonstrated effectiveness in clinical trials published in the Lancet and Nature Medicine, showing a 12% reduction in interval cancers and a 63.6% reduction in radiologist workload.